It Crushes Visceral Fat, But the Scale Barely Moves!

10:22

It Crushes Visceral Fat, But the Scale Barely Moves!

Physionic 28.05.2026 38 451 просмотров 2 036 лайков

Machine-readable: Markdown · JSON API · Site index

Смотреть на YouTube

Поделиться Telegram VK Бот

Транскрипт Скачать .md

Анализ с AI

Описание видео

*JOIN THE PHYSIONIC INSIDERS [PREMIUM CONTENT]* Join the Physionic Insiders: https://bit.ly/PhysionicInsiders2 *HEALTH AUTONOMY [COURSE]* Learn to Analyze & Apply Studies for Yourself: https://bit.ly/healthautonomy *JOIN THE COMMUNITY* Join my Community [It’s Free!]: https://bit.ly/PhysionicCommunity2 *EMAIL LIST* 1-2 Weekly Email of Value [It’s Free!]: http://bit.ly/2AXIzK6 *HIRE ME FOR CONSULTING:* Consulting: https://bit.ly/3dmUl2H Created with Biorender 0:00 - Introduction 1:15 - TH9507, by it’s Terminator Name 3:05 - Visceral Fat specific Exile 6:16 - HIV Specific or…? 8:07 - Safety (Higher IGF-1??) 9:20 - Not for Everyone, though Reducing Visceral Fat through a Food: https://www.youtube.com/watch?v=0Er08-E2HnU&t=1s The Best Peptide: https://www.youtube.com/watch?v=T9KJ8HGRmwM References* *Full Funding/Conflicts are provided in the free article (found in email list and Physionic Community Article Library) [1] Kadowaki T, Nishida T, Ogawa W, Overvad M, Tobe K, Yamauchi T. Effect of once-weekly subcutaneous semaglutide on abdominal visceral fat area in Japanese adults with overweight and obesity: A post hoc analysis of the STEP 6 trial. Obes Res Clin Pract. 2025;19(2):146-153. doi:10.1016/j.orcp.2025.03.003 [Study 788] Falutz J, Allas S, Kotler D, et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS. 2005;19(12):1279-1287. [Study 789] Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. [Study 790] Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-4304. doi:10.1210/jc.2010-0490. [Study 791] Stanley TL, Falutz J, Mamputu JC, Soulban G, Potvin D, Grinspoon SK. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction. AIDS. 2011;25(10):1281-1288. doi:10.1097/QAD.0b013e328347f3f1. [Study 792] Stanley TL, Falutz J, Marsolais C, et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012;54(11):1642-1651. doi:10.1093/cid/cis251. [Study 793] Makimura H, Feldpausch MN, Rope AM, Hemphill LC, Torriani M, Lee H, Grinspoon SK. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J Clin Endocrinol Metab. 2012;97(12):4769-4779. doi:10.1210/jc.2012-2794. [Study 794] Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. doi:10.1001/jama.2014.8334. [Study 795] Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019. Published online October 11, 2019. doi:10.1016/S2352-3018(19)30338-8. [Study 796] Lake JE, La K, Erlandson KM, et al. Tesamorelin improves fat quality independent of changes in fat quantity. AIDS. 2021;35(9):1395-1402. doi:10.1097/QAD.0000000000002897. [Study 797] Rahman F, McLaughlin T, Mesquita P, Morin J, Potvin D, De Chantal M, Aberg JA. Effect of tesamorelin in people with HIV with and without dorsocervical fat: post hoc analysis of phase III double-blind placebo-controlled trial. J Clin Transl Sci. 2023;7:e40. doi:10.1017/cts.2022.515. [Study 798] Russo SC, Ockene MW, Arpante AK, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024;38(12):1758-1764. doi:10.1097/QAD.0000000000003965. [Study 780] Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729. doi:10.1111/dom.16275 Please use the following link to submit your critique: https://bit.ly/PhysionicCritique Disclaimer: None of the information provided by this brand is a replacement for your physician's advice. This brand is information for the sake of knowledge and the options of choice it provides, not in any way a personalized prescription. Please consult your physician before making any health related changes.

Оглавление (6 сегментов)

Introduction

Visceral fat is a type of fat tissue that surrounds the organs and deeper sections of the body and is highly implicated in all sorts of diseases. Reducing the amount of visceral fat that we carry can have an immense impact on our overall health and reduce risk of chronic diseases. So, it piqued my interest when a physionic insider, Hank, hi Hank, reached out to me and turned me on to a new peptide, or what I thought was a new peptide that is believed to have an especially unique disappearing effect on visceral fat. Like I just alluded, the peptide seemed like it should be a new one, but it's actually been around for over two decades, though there's plenty more current research. So, I pulled together all the studies that I could find on the topic, 11 studies in total, to tease out if this special peptide really is so special in eliminating such a destructive type of body fat. This might throw you for a loop, but the initial data is based on studies done in people with HIV. Yes, the very same virus that causes AIDS. Now, in fact, most of the studies are done in people with HIV. But don't worry, this doesn't just apply to people with HIV. A couple of decades ago, this

TH9507, by it’s Terminator Name

study compared this peptide called TH9507, TH9507, to a placebo, a non-peptide exposed group. They discovered something striking, which was replicated in future studies like this one. But at this point, the peptide was no longer going by its Terminator name and had been rebranded to Tessaarelin, more of a Lord of the Rings elven name. I'd like to return to this HIV angle because it makes a difference in how we interpret this peptide's effects going forward. But for now, let's cover the effects of the peptide. Check this out. This is a measure of that very same visceral fat. The lower the bars, the more visceral fat loss. Now clearly compared to placebo but probably even compared to before taking the peptide tessorin cousin of galadriel there's a significant reduction in visceral fat. Now beyond that if we look at who is most affected there's an encouraging relationship shown here. We're measuring at the starting amount of visceral fat at the horizontal axis and the amount of change over months of the peptide use. Now in orange or no peptide use in the grayish blue. Now each dot and triangle is a participant's results. Notice how the line slants down in the peptide condition, the tesmarellin condition. That tells us that there is an association between having more visceral fat and experiencing greater benefit from the peptide. All this to say that the peptide is highly effective across multiple randomized placeboc controlled trials in reducing harmful visceral fat which is possibly a greater effect in those with large amounts of visceral fat to lose. Okay, so that is already pretty impressive but it's consistent across

Visceral Fat specific Exile

many studies. But that is not why tessimarid is unique across studies like the two that we just went briefly over. weight does not move much. So somehow there is a reduction in visceral fat but whole body weight doesn't budge. That's where tessimarillan's impact is unique. It leads to targeted anti-visisceral fat but has inconsistent and usually little effect on other types of fat in the body. Beyond that, it has a unique lean mass effect, meaning that it slightly increases lean mass, likely contributing to the no change in weight on the scale. This is actually why tessimarin h was so useful for people with on HIV drugs because these drugs could lead to unwanted redistribution of body fat, especially abnormal increases in the visceral fat. People with HIV can, though not all, have less active pituitary gland, which is closely tied to visceral fat accumulation as the pituitary is acted on by a hormone called the growth hormone releasing hormone or GHR that is released from another part of the brain, the hypothalamus. When bound to GH, the pituitary releases the actual growth hormone. So, GH, which then encourages fat cells to release fat, liberating it to be metabolized. Now, if this hormonal cascade is impeded somehow, like in some HIV cases, there can be an increasing accumulation of visceral fat. So tesamelin steps in because it mimics GHR the early step and binds the pituitary increasing growth hormone release. This is how it targets visceral fat which is especially sensitive to growth hormone. But remember I mentioned that tessamellin increases lean mass. That means that it increases either muscle, bone, cartilage or something else that is not fat. It does that likely because not only does it raise growth hormone, it significantly increases another molecule, IGF-1 or insulin like growth factor 1, which is elevated when the liver is bound by growth hormone. IGF-1 is known to stimulate cells to grow. So, I can't tell you that added lean mass is muscle specifically because no studies have measured it. We do get one clue from this study because researchers measured something called appendicular leass meaning they've excluded the trunk of the body and therefore exclude the growth of the hormone of the not hormones of the organs and there were some potential signs of growth that still doesn't improve muscle growth but it's a possibility nonetheless. The main takeaway here being that this peptide teslanin selectively reduces visceral fat of all body fat and it may increase lean mass though the composition of that lean mass is currently unknown. There

HIV Specific or…?

are however a few outstanding questions though. One, does this apply to people without HIV? And two, are there any safety concerns? And three, is this even worth any attention? If you're also interested in understanding how tessimarellin has a visceral fat healthifying effect, it's not a word, but its ability to change the quality of fat, its impact on the liver, and even how it might stack up against other peptides. And even more, then check out my full analysis included as a physionic insider. You get the video, obviously, you get a dedicated article, a one paragraph summary of the main takeaways, and much more. like all these perks right here. To join the insiders, use the link in the description. I'll see you there. Does this all apply to people without HIV? Well, it is true that almost all of the studies are HIV specific, but there are some studies that are in people without HIV. Fortunately, we see the results repeated here as well. So at least initial clinical evidence indicates tessamellin's visceral fat specific effects extend to people outside the HIV sphere. Still some context is yet to be applied because even this study excluded people with normal growth hormone secretion. So that doesn't offer evidence on people with normal growth hormone secretion. For that we'd have to lean back on some of the HIV studies that did not focus on people with reduced GH production. The best way to characterize this is to say that is likely that tessamellin would provide the same effects in people without HIV and likely even in people without reduced growth hormone production. Though that conclusion is based on a mixture of incomplete clinical data. Even so, considering the mechanism of

Safety (Higher IGF-1??)

action and considering the rises in growth stimulating molecule IGF-1 to twice or even close to three times previous values, it might raise some safety concerns and it may even narrow our takeaways further. Now, across all these studies, there weren't any major side effects detected except things like local swelling to the injection site, some muscle aches, and the like. Nothing major on an immediate effect. Although these studies did indicate a small increase in blood sugar as well. Still nothing overly alarming. Still, the longest of these studies last for about a year. So we don't have data on things like cancer concerns which might arise considering we have increased IGF-1 angle. While we don't have that specific data and while yes, there is a relatively large increase in growth molecule like IGF-1, the rise is still within normal physiological ranges. So, it's not out of the range. Plus, considering the overall health benefits, it still seems unlikely to me that the net effect would be putting a person in a worse situation. In the end, tessamel has a place in the peptide lineup. is

Not for Everyone, though

probably the peptide of choice for two different groups of people. One, people with chronically low growth hormone, something that would need to be tested. And two, for people who do not want to lose more weight and body fat. Keep in mind, some of the people may have visceral fat but may not be overweight. Something I've covered before, which is called tophi, thin outside, fat inside. So while unique and fascinating and especially attractive for some, a one or two milligram dose of testolanin is probably a peptide that may not have broad appeal but serves several unique use cases. Plus the visceral fat effect on its own is remarkable, I think. Now, if you're looking to learn more on visceral fat, then check this out right here. Otherwise, I have plenty of content on peptides right here, too. I hope you learned a thing or two. I know I did. Thanks again, Hank, for turning me on to Tessa, as the cool kids call it. I'll catch you in the next one.

Другие видео автора — Physionic

Ctrl+V

Экстракт Знаний в Telegram

Экстракты и дистилляты из лучших YouTube-каналов — сразу после публикации.

Подписаться

Лучшие методички за неделю — каждый понедельник